IP Library › Granted Patent US 12,378,236
Granted Patent B2
US 12,378,236 · App. 19/018,754 · Granted Aug 5, 2025

Compounds as GLP-1R agonists

Inventors: Corey Reeves (Foster City, CA); F. Anthony Romero (Redwood City, CA); Christopher T. Jones (Foster City, CA); Martijn Fenaux (San Mateo, CA)
Assignee: Terns Pharmaceuticals, Inc.
C07D417/14A61P3/04A61P3/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,378,236
App. No.
19/018,754
Granted
Aug 5, 2025
Kind
B2
Abstract

The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof. Methods of preparing these compounds and compositions, and methods of using these compounds and compositions to treat or prevent a disease or a condition mediated by GLP-1R, are also provided.

Claims (24)

1. A compound selected from

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein the compound is

4. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein the compound is

6. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , wherein the compound is

8. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

9. A pharmaceutical composition comprising the compound of claim 2 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

10. A pharmaceutical composition comprising the compound of claim 4 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

11. A pharmaceutical composition comprising the compound of claim 6 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

12. The compound of claim 2 , wherein the compound is a meglumine salt of the compound.

13. A pharmaceutical composition comprising the compound of claim 12 and a pharmaceutically acceptable excipient.

14. A method of treating a disease mediated by glucagon-like peptide-1 receptor (GLP-1R) in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of the compound of claim 2 , or a pharmaceutically acceptable salt thereof.

15. The method of claim 14 , where the disease is a liver disease.

16. A method of treating diabetes in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of the compound of claim 2 , or a pharmaceutically acceptable salt thereof.

17. A method of treating cardiometabolic disease in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of the compound of claim 2 , or a pharmaceutically acceptable salt thereof.

18. A method of treating obesity in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of the compound of claim 2 , or a pharmaceutically acceptable salt thereof.

19. A method of decreasing food intake in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of the compound of claim 2 , or a pharmaceutically acceptable salt thereof.

20. A method of increasing glucose tolerance in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of the compound of claim 2 , or a pharmaceutically acceptable salt thereof.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2025
From: FENAUX, MARTIJN
To: TERNS PHARMACEUTICALS, INC.
Reel/Frame 070033/0975 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2025
From: REEVES, COREY; ROMERO, F. ANTHONY; JONES, CHRISTOPHER T.
To: TERNS, INC.
Reel/Frame 070033/0983 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2025
From: TERNS, INC.
To: TERNS PHARMACEUTICALS, INC.
Reel/Frame 070033/0992 →
Continuity (4)
Continuation 18956385 · Nov 22, 2024
Continuation 17954047 · Sep 27, 2022
Provisional Application 63261717 · Sep 27, 2021
Related Publication 20250145612A1 · May 8, 2025
References Cited (241)
US 5665732A · Baker et al. · 1997 [cited by applicant]
US 5714498A · Kulagowski et al. · 1998 [cited by applicant]
US 5763263A · Dehlinger · 1998 [cited by applicant]
US 5780475A · Baker et al. · 1998 [cited by applicant]
US 9764003B2 · Jensen · 2017 [cited by applicant]
US 10208019B2 · Aspnes et al. · 2019 [cited by applicant]
US 10335462B2 · Jensen · 2019 [cited by applicant]
US 10669259B2 · Aspnes et al. · 2020 [cited by applicant]
US 10844049B2 · Zhong · 2020 [cited by applicant]
US 10851081B2 · Aspnes et al. · 2020 [cited by applicant]
US 11512070B2 · Aspnes et al. · 2022 [cited by applicant]
US 11584751B1 · Ren et al. · 2023 [cited by applicant]
US 11918623B2 · Corvari et al. · 2024 [cited by applicant]
US 12024507B2 · Reeves · 2024 [cited by examiner]
US 20030162790A1 · Cowart et al. · 2003 [cited by applicant]
US 20030176438A1 · Arienti et al. · 2003 [cited by applicant]
US 20040127504A1 · Cowart et al. · 2004 [cited by applicant]
US 20050004114A1 · Whitehouse et al. · 2005 [cited by applicant]
US 20070244126A1 · Edwards et al. · 2007 [cited by applicant]
US 20080280933A1 · Efremov et al. · 2008 [cited by applicant]
US 20120028959A1 · Thunuguntla et al. · 2012 [cited by applicant]
US 20180170908A1 · Aspnes et al. · 2018 [cited by applicant]
US 20190119255A1 · Aspnes et al. · 2019 [cited by applicant]
US 20200071306A1 · Esler et al. · 2020 [cited by applicant]
US 20210047298A1 · Aspnes et al. · 2021 [cited by applicant]
US 20220016136A1 · Lian et al. · 2022 [cited by applicant]
US 20220089578A1 · Romero et al. · 2022 [cited by applicant]
US 20220348564A1 · Ren et al. · 2022 [cited by applicant]
US 20230124938A1 · Aspnes et al. · 2023 [cited by applicant]
US 20230150998A1 · Reeves et al. · 2023 [cited by applicant]
US 20230159512A1 · Reeves et al. · 2023 [cited by applicant]
US 20230322744A1 · Romero et al. · 2023 [cited by applicant]
US 20230322758A1 · Reeves et al. · 2023 [cited by applicant]
US 20240360122A1 · Bian et al. · 2024 [cited by applicant]
US 20240368120A1 · Luehr et al. · 2024 [cited by applicant]
US 20240391910A1 · Reeves · 2024 [cited by examiner]
CN 113480534A · 2021 [cited by applicant]
CN 113493447A · 2021 [cited by applicant]
EP 3555064B1 · 2022 [cited by applicant]
JP 2019099571A · 2019 [cited by applicant]
TW 202128659A · 2021 [cited by applicant]
WO WO2010114957A1 · 2010 [cited by applicant]
WO WO2011143365A1 · 2011 [cited by applicant]
WO WO2015166398A1 · 2015 [cited by applicant]
WO WO2018056453A1 · 2018 [cited by applicant]
WO WO2018109607A1 · 2018 [cited by applicant]
WO WO2019239319A1 · 2019 [cited by applicant]
WO WO2019239371A1 · 2019 [cited by applicant]
WO WO2020103815A1 · 2020 [cited by applicant]
WO WO2020207474A1 · 2020 [cited by applicant]
WO WO2020263695A1 · 2020 [cited by applicant]
WO WO2021018023A1 · 2021 [cited by applicant]
WO WO2021081207A1 · 2021 [cited by applicant]
WO WO2021096284A1 · 2021 [cited by applicant]
WO WO2021096304A1 · 2021 [cited by applicant]
WO WO2021112538A1 · 2021 [cited by applicant]
WO WO2021116874A1 · 2021 [cited by applicant]
WO WO2021154796A1 · 2021 [cited by applicant]
WO WO2021155841A1 · 2021 [cited by applicant]
WO WO2021160127A1 · 2021 [cited by applicant]
WO WO2021187886A1 · 2021 [cited by applicant]
WO WO2021197464A1 · 2021 [cited by applicant]
WO WO2021219019A1 · 2021 [cited by applicant]
WO WO2021242817A1 · 2021 [cited by applicant]
WO WO2021244391A1 · 2021 [cited by applicant]
WO WO2021244645A1 · 2021 [cited by applicant]
WO WO2021249492A1 · 2021 [cited by applicant]
WO WO2021254470A1 · 2021 [cited by applicant]
WO WO2021259309A1 · 2021 [cited by applicant]
WO WO2022007979A1 · 2022 [cited by applicant]
WO WO2022017338A1 · 2022 [cited by applicant]
WO WO2022028572A1 · 2022 [cited by applicant]
WO WO2022031994A1 · 2022 [cited by applicant]
WO WO2022040600A1 · 2022 [cited by applicant]
WO WO2022042691A1 · 2022 [cited by applicant]
WO WO2022048665A1 · 2022 [cited by applicant]
WO WO2022052958A1 · 2022 [cited by applicant]
WO WO2022068772A1 · 2022 [cited by applicant]
WO WO2022078152A1 · 2022 [cited by applicant]
WO WO2022078352A1 · 2022 [cited by applicant]
WO WO2022078380A1 · 2022 [cited by applicant]
WO WO2022078407A1 · 2022 [cited by applicant]
WO WO2022109182A1 · 2022 [cited by applicant]
WO WO2022111624A1 · 2022 [cited by applicant]
WO WO2022116693A1 · 2022 [cited by applicant]
WO WO2022135572A1 · 2022 [cited by applicant]
WO WO2022165076A1 · 2022 [cited by applicant]
WO WO2022192428A1 · 2022 [cited by applicant]
WO WO2022192430A1 · 2022 [cited by applicant]
WO WO2022199458A1 · 2022 [cited by applicant]
WO WO2022199661A1 · 2022 [cited by applicant]
WO WO2022202864A1 · 2022 [cited by applicant]
WO WO2022207950A1 · 2022 [cited by applicant]
WO WO2022216094A1 · 2022 [cited by applicant]
WO WO2022219495A1 · 2022 [cited by applicant]
WO WO2022225941A1 · 2022 [cited by applicant]
WO WO2022228490A1 · 2022 [cited by applicant]
WO WO2022235717A1 · 2022 [cited by applicant]
WO WO2022246019A1 · 2022 [cited by applicant]
WO WO2022258805A1 · 2022 [cited by applicant]
WO WO2022268152A1 · 2022 [cited by applicant]
WO WO2023000834A1 · 2023 [cited by applicant]
WO WO2023001237A1 · 2023 [cited by applicant]
WO WO2023011539A1 · 2023 [cited by applicant]
WO WO2023016546A1 · 2023 [cited by applicant]
WO WO2023028606A1 · 2023 [cited by applicant]
WO WO2023029380A1 · 2023 [cited by applicant]
WO WO2023031741A1 · 2023 [cited by applicant]
WO WO2023038039A1 · 2023 [cited by applicant]
WO WO2023049518A1 · 2023 [cited by applicant]
WO WO2023057414A1 · 2023 [cited by applicant]
WO WO2023057427A1 · 2023 [cited by applicant]
WO WO2023057429A1 · 2023 [cited by applicant]
WO WO2023066356A1 · 2023 [cited by applicant]
WO WO2023076237A1 · 2023 [cited by applicant]
WO WO2023103310A1 · 2023 [cited by applicant]
WO WO2023106310A1 · 2023 [cited by applicant]
WO WO2023111144A1 · 2023 [cited by applicant]
WO WO2023111145A1 · 2023 [cited by applicant]
WO WO2023124824A1 · 2023 [cited by applicant]
WO WO2023138684A1 · 2023 [cited by applicant]
WO WO2023151574A1 · 2023 [cited by applicant]
WO WO2023151575A1 · 2023 [cited by applicant]
WO WO2023152698A1 · 2023 [cited by applicant]
WO WO2023164050A1 · 2023 [cited by applicant]
WO WO2023164358A1 · 2023 [cited by applicant]
WO WO2023169456A1 · 2023 [cited by applicant]
WO WO2023179542A1 · 2023 [cited by applicant]
WO WO2023198140A1 · 2023 [cited by applicant]
WO WO2023222084A1 · 2023 [cited by applicant]
WO WO2023222124A1 · 2023 [cited by applicant]
WO WO2024041609A1 · 2024 [cited by applicant]
WO WO2024046342A1 · 2024 [cited by applicant]
WO WO2024051700A1 · 2024 [cited by applicant]
WO WO2024063140A1 · 2024 [cited by applicant]
WO WO2024063143A1 · 2024 [cited by applicant]
WO WO2024102625A1 · 2024 [cited by applicant]
WO WO2024107781A1 · 2024 [cited by applicant]
WO WO2024131869A1 · 2024 [cited by applicant]
WO WO2024149080A1 · 2024 [cited by applicant]
WO WO2024206647A1 · 2024 [cited by applicant]
WO WO2024206878A1 · 2024 [cited by applicant]
Russak EM, Bednarczyk EM. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Annals of Pharmacotherapy. 2018;53(2):211-216 (Year: 2018). [cited by examiner]
Brown, Bioisosteres in Medicinal Chemistry, 2012 (Year: 2012). [cited by examiner]
Ballatore, C., Huryn, D.M. and Smith, A.B., III (2013), Carboxylic Acid (Bio)Isosteres in Drug Design. ChemMedChem, 8: 385-395 (Year: 2013). [cited by examiner]
1H-Benzimidazole-6-carboxylic acid, 2-[[4-[(2S)-2-(5-chloro-2-pyridinyl)-2-methyl-1,3-benzodioxol-4-yl]-1-piperidinyl]methyl]-1-[(2S)-2-oxetanylmethyl]-, Chemical Book, 2017, 2 pages. [cited by applicant]
Ahmad, I., et al., “Xanthine oxidase/tyrosinase inhibiting, antioxidant, and antifungal oxindole alkaloids from Isatis costata,” Pharmaceutical Biology, 2010, 48(6), pp. 716-721. [cited by applicant]
Arshad, M. F., et al., “Thiazole: A Versatile Standalone Moiety Contributing to the Development of Various Drugs and Biologically Active Agents,” Molecules 2022, 27, 3994, https://doi.org/10.3390/molecules27133994, 54 p… [cited by applicant]
Balaban, A. T., et al., Aromaticity as a Cornerstone of Heterocyclic Chemistry, Chem. Rev. 2004, 104, 2777-2812. [cited by applicant]
Beker, W, et al., “Reactivity Patterns of Imidazole, Oxazole, and Thiazole as Reflected by the Polarization Justified Fukui Functions,” J. Phys. Chem. A 2013, 117, 1596-1600. [cited by applicant]
Belaidi, S., et al., “Electronic Structure and Physico-Chemical Property Relationship for Thiazole Derivatives,” Asian Journal of Chemistry, 2013, vol. 25, No. 16, 9241-9245. [cited by applicant]
Beulah, K., et al., “Design, Synthesis and Biological Evaluation of Benzimidazole-pyridine-Piperidine Hybrids as a New Class of Potent Antimicrobial Agents,” Letters in Drug Design & Discovery, 2015, vol. 12, No. 1, pp.… [cited by applicant]
Bjerregaard, L. G., et al., “Change in Overweight from Childhood to Early Adulthood and Risk of Type 2 Diabetes,” The New England Journal of Medicine, Apr. 5, 2018, 378(14):1302-1312, DOI: 10.1056/NEJMoa1713231 Doi: 10.… [cited by applicant]
Blanco, F. J., et al., “Effect of Antiinflammatory Drugs on COX-1 and COX-2 Activity in Human Articular Chondrocytes,” The Journal of Rheumatology, 1999, 26:6, pp. 1366-1373. [cited by applicant]
Blanpied, T. A., et al., “Trapping Channel Block of NMDA-Activated Responses by Amantadine and Memantine,” The American Physiological Society, 1997, pp. 309-323. [cited by applicant]
Buckeridge, C. et al., “Once-daily oral small molecule GLP-1R agonist PF-07081532 robustly reduces glucose and body weight within 4-6 weeks in adults with type 2 diabetes and non-diabetic adults with obesity,” EASD Pres… [cited by applicant]
Chen, L., et al., “Discovery of Novel 5,6-Dihydro-1,2,4-triazine Derivatives as Efficacious Glucagon-Like Peptide-1 Receptor Agonists,” Journal of Medicinal Chemistry 2023, 66, pp. 7988-8010. [cited by applicant]
Coll, B., et al., “A Phase 1b/2a Study of the Safety and Tolerability of GSBR-1290, a Novel Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA), in Healthy Overweight/Obese Volunteers (HOV) and Partic… [cited by applicant]
Davies, D. T., Aromatic Heterocyclic Chemistry, Chapters 3 and 4, Oxford University Press 1992, 21 pages. [cited by applicant]
Dolomanov, O. V., et al., “OLEX2: a complete structure solution, refinement and analysis program,” J. Appl. Cryst. 2009, 42, 339-341, doi:10.1107/S0021889808042726. [cited by applicant]
Dorwald, Side Reactions in Organic Synthesis. Wiley-VCH, pp. 1-16 (2005). [cited by applicant]
Escobar-Morreale, H. F., “Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment,” Nature Reviews Endocrinology, May 2018, vol. 14, pp. 270-284, doi: 10.1038/nrendo.2018.24. [cited by applicant]
Extended European Search Report for European Application No. 21859247.5 mailed Nov. 27, 2024, 15 pages. [cited by applicant]
Farrugia, L. J., “WinGX and ORTEP for Windows: an update,” Applied Crystallography 2012, 45, 849-854, doi:10.1107/S0021889812029111. [cited by applicant]
Flack , H. D., “On Enantiomorph-Polarity Estimation,” Acta Cryst. 1983, A39, 876-881. [cited by applicant]
Flack, H. D., et al., “The Use of X-ray Crystallography to Determine Absolute Configuration,” Chirality 20:681-690, 2008, DOI: 10.1002/chir.20473. [cited by applicant]
Griffith, D. A., et al., “A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor,” Journal of Medicinal Chemistry, 2022, 65, pp. 8208-8226. [cited by applicant]
Guerrero-Pepinosa, N. Y., et al., “Antiproliferative activity of thiazole and oxazole derivatives: A systematic review of in vitro and in vivo studies,” Biomedicine & Pharmacotherapy 138 (2021) 111495, https://doi.org/1… [cited by applicant]
Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. US Department of Health and Human Services, Food and Drug Administration (FDA), C… [cited by applicant]
Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. U.S. Department of Health and Human Services, Food and Drug Administration, Cente… [cited by applicant]
Haake, P., et al., “A Comparison of Thiazoles and Oxazoles,” Communications to the Editor, vol. 85, Dec. 20, 1963, pp. 4044-4045. [cited by applicant]
Haberhauer, G., et al., “Structural Investigation of Westiellamide Analogues,” Tetrahedron 2008, 64, 1853-1859. [cited by applicant]
Hamdan, F., et al., “Synthesis of novel cyclopeptides containing heterocyclic skeletons,” RSC Advances 2018, 8, 33893-33926, DOI: 10.1039/c8ra03899f. [cited by applicant]
Hampp, C. et al., “Use of Antidiabetic Drugs in the U.S., 2003-2012,” Diabetes Care, May 2014, vol. 37, pp. 1367-1374, DOI: 10.2337/dc13-2289. [cited by applicant]
Holst, J. J., et al., The Physiology of Glucagon-like Peptide 1, Physiological Reviews, 2007, vol. 87, pp. 1409-1439, doi:10.1152/physrev.00034.2006. [cited by applicant]
Hooft, R. W. W., et al., “Determination of absolute structure using Bayesian statistics on Bijvoet differences,” J. Appl. Cryst. 2008, 41, 96-103, doi:10.1107/S0021889807059870. [cited by applicant]
Horner, K. E., et al., “Shielding in and around Oxazole, Imidazole, and Thiazole: How Does the Second Heteroatom Affect Aromaticity and Bonding?,” J. Org. Chem. 2015, 80, 7150-7157. [cited by applicant]
Huang, K.-P., et al., “Dissociable hindbrain GLP1R circuits for satiety and aversion,” Nature, Aug. 15, 2024, vol. 632, pp. 585-593, including Methods, Extended Data & Reporting Summary, 25 pages, https://doi.org/10.103… [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2022/047687, mailed May 10, 2024, 8 pages. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2023/013700 mailed Sep. 6, 2024 8 pages. [cited by applicant]
International Preliminary Report on Patentability, mailed Apr. 11, 2024, for International Application No. PCT/US2022/044915, 8 pages. [cited by applicant]
International Preliminary Report on Patentability, mailed Mar. 2, 2023, for International Application No. PCT/US2021/047015, 8 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/047015, mailed Jan. 13, 2022, 11 Pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/047687, mailed Feb. 16, 2023, 13 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2024/021994 mailed Jul. 30, 2024, 16 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2024/022311 mailed Aug. 14, 2024, 19 pages. [cited by applicant]
International Search Report and Written Opinion, mailed Apr. 28, 2023, for International Application No. PCT/US2023/013700, 11 pages. [cited by applicant]
International Search Report and Written Opinion, mailed Dec. 5, 2022, for International Application No. PCT/US2022/044915 (13 total pages). [cited by applicant]
Invitation to Pay Additional Fees and, Where Applicable, Protest Fee for International Application No. PCT/US2024/022311, mailed Jun. 24, 2024, 14 pages. [cited by applicant]
Invitation to Pay Additional Fees and, Where Applicable, Protest Fee, mailed Oct. 25, 2021, for International Application No. PCT/US2021/047015 (2 total pages). [cited by applicant]
Kalra, S., et al., “Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force,” Diabetes Ther 2019, 10: 1645-1717, https://doi.org/10.1007/s13300-019-0669-4. [cited by applicant]
Kaspady, M., et al., “Synthesis, Antibacterial Activity of 2,4-Disubstituted Oxazoles and Thiazoles as Bioisosteres,” Letters in Drug Design & Discovery, 2009, 6, pp. 21-28. [cited by applicant]
Krieger, J.-P., “Intestinal glucagon-like peptide-1 effects on food intake: Physiological relevance and emerging mechanisms,” Peptides 2020, 131:170342, 8 pages, https://doi.org/10.1016/j.peptides.2020.170342. [cited by applicant]
Lega, I. C., et al., “Review: Diabetes, Obesity, and Cancer-Pathophysiology and Clinical Implications,” Endocrine Reviews, Feb. 2020, 41(1):35-52, doi:10.1210/endrev/bnz014. [cited by applicant]
Macrae, C. F., et al., “Mercury: visualization and analysis of crystal structures,” J. Appl. Cryst. 2006, 39, 453-457, doi: 10.1107/S002188980600731X. [cited by applicant]
Meier, J. J., et al., “Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide,” Biodrugs 2003, 17(2), pp. 93-102. [cited by applicant]
Meier, J. J., “GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus,” Nature Reviews Endocrinology, Dec. 2012, vol. 8, p. 728-742, Published online Sep. 4, 2012, doi:10.1038/nrendo.2012.140. [cited by applicant]
Muller, T.D., et al., “Anti-Obesity Therapy: from Rainbow Pills to Polyagonists,” Pharmacological Reviews, Oct. 2018, 70: 712-746, doi:10.1124/pr.117.014803. [cited by applicant]
Nauck, M. A., et al., “Another milestone in the evolution of GLP-1-based diabetes therapies,” Nature Medicine, vol. 27, Jun. 2021, pp. 949-953. [cited by applicant]
NCT01237119: “Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis (LEAN),” Aug. 2010, Phase 2, 7 pages, Retrieved on Feb. 13, 2025, Retrieved from https://clinicaltrials.gov/study/NCT01237119. [cited by applicant]
NCT03590626. “Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease (D-LIFT),” Jan. 1, 2019, 11 pages, Retrieved on Feb. 13, 2025, Retrieved from https://clinicaltrials… [cited by applicant]
Ognyaov, V. I., et al., “Design of Potent, Orally Available Antagonists of the Transient Receptor Potential Vanilloid 1. Structure-Activity Relationships of 2-Piperazin-1-yl-1H-benzimidazoles,” J. Med Chem, 2006, vol. 4… [cited by applicant]
Partial Supplementary European Search Report for European Application No. 21859247.5 dated Sep. 6, 2024, 16 pages. [cited by applicant]
Pathway: HSA04911, Insulin secretion— [cited by applicant]
Pfizer Press release—Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity, Dec. 1, 2023, 4 pages, businesswire.com: https://www.businesswire.com/news/home/20231130108413/… [cited by applicant]
Plamboeck, A., et al., “The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty,” Am J Physiol Gastrointest Liver Physiol 304: G1117-G1127, 2013, https://doi.org/10.… [cited by applicant]
Polyzos, S. A., et al., “Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics,” Metabolism Clinical and Experimental 2019, 92:82-97, doi:10.1016/j.metabol.2018.11.014. [cited by applicant]
Priner, M et al., “94-LB: A Phase 1, Double-Blind, Placebo-Controlled Multiple Escalating Dose Study of RGT-075 Novel Small-Molecule Oral GLP-1 Receptor Agonist in Adults with Type 2 Diabetes,” Diabetes 2022;71 (Supplem… [cited by applicant]
PUBCHEM “Danuglipron,” CID: 134611040, Created Jun. 23, 2018; Modified Feb. 8, 2025, 32 pages, Retrieved on Feb. 13, 2025, Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/134611040#section=Information-Sources. [cited by applicant]
Roche, Ad hoc announcement pursuant to Art. 53 LR, “Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity,” Jul. 17, 2024, 5 pages, https://www.roche… [cited by applicant]
Saxena, A., et al., “Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study c… [cited by applicant]
Saxena, A. R., et al., “Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial,” Nature Medicine, vol. 27, Jun. 2021, pp. 1079-1087, doi: 10.1038/s41591-021… [cited by applicant]
Saxena, A. R., et al., “Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial,” JAMA Networ… [cited by applicant]
Saxenda® (liraglutide) injection, for subcutaneous use. United States Prescribing Information (USPI). 2022. Accessed: Feb. 2, 2023. 13 pages. https://www.novo-pi.com/saxenda.pdf. [cited by applicant]
Shaffer, A. A, et al., “Comparison of Computational Methods Applied to Oxazole, Thiazole, and Other Heterocyclic Compounds,” Journal of Computational Chemistry, vol. 14, No. 1, pp. 75-88 (1993). [cited by applicant]
Sharma, M. C., “QSAR studies of novel 1-(4-methoxyphenethyl)-1H-benzimidazole-5-carboxylic acid derivatives and their precursors as antileukaemic agents,” Journal of Taibah University for Science, 2016, vol. 10, pp. 122… [cited by applicant]
Sheldrick, G. M., “Crystal structure refinement with SHELXL,” ActaCryst. 2015, C71, 3-8, doi:10.1107/S2053229614024218. [cited by applicant]
Sheldrick, G. M., “SHELXL—Integrated space-group and crystal-structure determination” ActaCryst. 2015, A71, 3-8, doi:10.1107/S2053273314026370. [cited by applicant]
Sloop, K. W., et al., “Novel Small Molecules Glucagon-Like Peptide-1 Receptor Agonist Stimulates Isulin Secretion in Rodents and From Human Islets,” Diabetes, vol. 59, Dec. 2010, p. 3099-3107. [cited by applicant]
Stas, M., et al., “Thiazole-amino acids: influence of thiazole ring on conformational properties of amino acid residues,” Amino Acids 2021, 53: 673-686, https://doi.org/10.1007/s00726-021-02974-0. [cited by applicant]
Stemmer, K., et al., “CNS-targeting pharmacological interventions for the metabolic syndrome,” The Journal of Clinical Investigation, Oct. 2019, 129(10), pp. 4058-4071, https://www.jci.org/articles/view/129195/pdf. [cited by applicant]
Stevens, E., Medicinal Chemistry: The Modern Drug Discovery Process, 2013, Chapter 10, Lead Discovery, pp. 247-272. [cited by applicant]
Structure Therapeutics Corporate Presentation, GSBR-1290 Phase 1b MAD Results. Sep. 29, 2023, 24 pages. [cited by applicant]
Teague, S. J., et al., “The Design of Leadlike Combinatorial Libraries,” Communications, Angew. Chem. Int. Ed., 1999, 38, No. 24, pp. 3743-3748. [cited by applicant]
Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity, Sep. 9, 2024, 3 pages, retrieved on Feb. 12, 2025, retrieved from URL: h… [cited by applicant]
Twig, G., et al., “Body-Mass Index in 2.3 Million Adolescents and Cardiovascular Death in Adulthood,” The New England Journal of Medicine, Jun. 23, 2016, 374;25: 2430-2440, DOI: 10.1056/NEJMoa1503840. [cited by applicant]
U.S. Appl. No. 18/956,385, filed Nov. 22, 2024, by Reeves et al. [cited by applicant]
U.S. Appl. No. 19/018,773, filed Jan. 13, 2025, by Reeves et al. [cited by applicant]
U.S. Appl. No. 19/018,788, filed Jan. 13, 2025, by Reeves et al. [cited by applicant]
U.S. Appl. No. 19/018,805, filed Jan. 13, 2025, by Reeves et al. [cited by applicant]
U.S. Appl. No. 19/018,817, filed Jan. 13, 2025, by Reeves et al. [cited by applicant]
Vilsboll, T., et al., Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients, Diabetes, vol. 50, Mar. 2001, pp. 609-613. [cited by applicant]
Waise, T. M. Z., et al., The metabolic role of vagal afferent innervation, Nature Reviews Gastroenterology & Hepatology, vol. 15, Oct. 2018, pp. 625-636, https://doi.org/10.1038/s41575-018-0062-1. [cited by applicant]
Wegovy® (semaglutide) injection, for subcutaneous use. United States Prescribing Information (USPI). 2023. Accessed: Feb. 2, 2023. 15 pages. https://www.novo-pi.com/wegovy.pdf. [cited by applicant]
Zhang, X. et al., “Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists,” Molecular Cell 80, Nov. 5, 2020; pp. 485-500 & 485-500.e1-e7, doi: 10.1016/j.molcel.2020.09.020. [cited by applicant]
GenBank Accession No. NM_002062.5. Version No. NM_002062.5. [cited by applicant]
Pfizer. Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron. Apr. 14, 2025. [retrieved on May 7, 2025] Available at: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-or… [cited by applicant]
Remington: The Science and Practice of Pharmacy, 21st Edition. Lippincott Williams & Wilkins (2005). [cited by applicant]
Terns. Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with Tern-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity. Sep. 9, 2024. [retrieved on May 7, 2025] Available at: https://ir… [cited by applicant]
Terns. Terns Pharmaceuticals. Our Programs. [retrieved May 7, 2025] Available at: https://www.ternspharma.com/our-programs. pp. 6. [cited by applicant]
Wuts, Peter G M, and Theodora W. Greene. Greene's Protective Groups in Organic Synthesis, 4th Edition. Wiley (2006). [cited by applicant]
Cited By (1)
US 12,485,118